drugset / Trial / NCT04408183
GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19)
RandomizedParallel-groupTriple-blindPrevention
Summary
This clinical trial will evaluate the safety, tolerability and effectiveness of topical GLS-1200 nasal spray to reduce the incidence of confirmed, symptomatic SARS-CoV-2 infection.
Timeline
- Start
- 2020-06-10
- Primary completion
- 2023-01-10
- Completion
- 2023-01-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Quinine | Small molecule | 1 ml | Intranasal |